Survey: Tourette Syndrome Patients Report Subjective Benefits from Cannabis

Thursday, 16 January 2020

Hannover, Germany: The use of cannabis and cannabinoids is associated with subjective benefits in patients with Tourette Syndrome (TS), according to survey data published in the journal Cannabis and Cannabinoid Research.

Investigators from Hannover Medical School in Germany and the Medical University of Warsaw in Poland surveyed 98 TS patients who had prior experience with the use of medical cannabis products. Eighty-five percent of respondents said that cannabis mitigated their symptoms and 93 percent reported that it improved their quality of life.

Among those subjects who expressed a preference, most said that they believed herbal cannabis is more effective than either synthetic products (e.g., dronabinol) or oral tinctures (e.g., nabiximols).

Full text of the study, "Treatment of Gilles de la Tourette Syndrome in cannabis-based medicine: Results from a retrospective analysis and online survey," appears in Cannabis and Cannabinoid Research. Additional information on cannabinoids and TS is available from NORML.